Condition: Diffuse Cutaneous Systemic Sclerosis · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| Arizona Arthritis and Rheumatology Research PLLC | Mesa, Arizona, United States | Recruiting |
| UCLA | Los Angeles, California, United States | Recruiting |
| Hoag Hospital | Newport Beach, California, United States | Recruiting |
| Clinical Res Of W Florida | Clearwater, Florida, United States | Recruiting |
| GNP Research | Cooper City, Florida, United States | Recruiting |
| IRIS Research and Development | Plantation, Florida, United States | Recruiting |
| Sarasota Arthritis Res Ctr | Sarasota, Florida, United States | Recruiting |
| University of Chicago Hospitals | Chicago, Illinois, United States | Recruiting |
| UMC New Orleans | New Orleans, Louisiana, United States | Recruiting |
| Uni Of Michigan Health System | Ann Arbor, Michigan, United States | Recruiting |
| Wayne State University | Detroit, Michigan, United States | Recruiting |
| Clinical Research Inst of MI | Saint Clair Shores, Michigan, United States | Recruiting |
+ 116 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06470048